The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,670.00
Bid: 1,670.50
Ask: 1,671.00
Change: 17.00 (1.03%)
Spread: 0.50 (0.03%)
Open: 1,650.00
High: 1,677.00
Low: 1,646.00
Prev. Close: 1,670.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Dunelm's spooky "severe but plausible downside" scenario

Thu, 10th Sep 2020 11:50

Welcome to the home for real-time coverage of European equity markets brought to you by Reuters
stocks reporters. You can share your thoughts with Joice Alves (joice.alves@thomsonreuters.com)
and Julien Ponthus (julien.ponthus@thomsonreuters.com) in London and Danilo Masoni and Stefano
Rebaudo (stefano.rebaudo@thomsonreuters.com) in Milan.

DUNELM'S SPOOKY "SEVERE BUT PLAUSIBLE DOWNSIDE" SCENARIO (1039 GMT)

There's been quite a bit of disappointment to see the shares in British home furnishing
retailer Dunelm retreat this morning despite the encouraging sales achieved in the face
of the coronavirus pandemic.

Much of today's negative price action seems to be blamed on profit taking and on the
decision of Dunelm, a clear lockdown winner, to play it safe and to keep some cash for the
possible rainy days ahead.

"Despite strong current trading, a still uncertain outlook and 'prudent financial approach'
means the Board has chosen not to declare a final dividend for FY20 and management has not
issued FY21 PBT guidance", UBS analysts noted.

But another important part of Dunelm's earnings which might have spooked investors is the
retailer's assessment of what could go wrong.

"There is a fear stalking some companies", commented Neil Wilson at Markets.com, noting the
group's warning of a "severe but plausible" downside scenario which involves lockdowns over
Christmas.

Here's how Dunelm describes in its press release what could happen in a few months to its
business, but by extension to most European retailers:

"The 'severe but plausible downside' scenario is very conservative in assuming a further
national lockdown for ten weeks where our stores are no longer in the 'permitted' status and
where we are unable to offer our Click & Collect service.

We have also assumed that this national lockdown occurs in our peak Christmas and Winter
Sale trading period, with all of the Group's stores being required to shut for ten weeks in the
event of a second Covid-19 outbreak, on top of the downturn in the economy that is already
included in the central case, including potential Brexit-related disruption."

Yikes and merry Xmas everybody!

On a more positive note for Dunelm shareholders, the company "has been a clear relative
winner in the sector through the crisis, with possibly some lasting benefits from strong
customer acquisition," JP Morgan analysts believe.

Anyhow, here's how Dunelm has outperformed the FTSE 250 and how it's comparing with other
top retailers so far in 2020:

(Julien Ponthus)

*****

WHAT ABOUT A PE RATIO OF 100? (0955 GMT)

These days more than ever stock valuations seem to be a matter of how much cash is lying on
the sidelines as central banks are in a "whatever it takes" mood to pour liquidity in order to
avoid the adverse impact of the virus.

Jeroen Blokland, portfolio manager at Robeco, crunched some numbers to measure the
relationship between excess liquidity -- as the difference between money supply and nominal GDP
growth -- and the PE of the S&P 500 stocks.

He concludes that the PE ratio should be at a whooping 100, from around 28 these days.

"Obviously, this is not going to happen, also because nominal GDP growth is expected to
bounce back sharply," he says in a research note. "But it does point out that from a liquidity
perspective, valuation looks far from stretched".

The idea behind this is that if there is more money than needed for economic growth, excess
liquidity will find its way into the stock market.

(Stefano Rebaudo)

*****

BREXIT TURBO-CHARGES UK RISK PREMIA (0850 GMT)

Risk premia on UK assets are rising and will continue to do so as investors fear a messy
divorce with the European Union when Britain finally disentangles at the end of the year.

The European Union could take legal action under its divorce treaty with Britain if today’s
emergency talks do not reassure Brussels sufficiently that a proposed new British law will not
break previously agreed commitments.

An ABN Amro research note recalls that, inside the bond bank index, NatWest Group
over the last seven days staged "the largest underperformance, with their bail-in senior bonds
moving over 30bps wider."

Other names, such as Lloyds and Barclays have only performed a few basis
points better while HSBC, Santander UK and Standard Chartered have suffered a
20 basis points hit.

ABN Amro analysts anticipate that the Brexit negotiations will continue to produce negative
headlines with little achieved in the forthcoming weeks. "UK risks premiums are likely to stay
elevated for the remainder of this year," they say.

The bank index is at 79 basis points (bps) above the swap, roughly 29 bps wider than before
the coronavirus crisis and 158 bps tighter than the pandemic highs experienced in March.

(Stefano Rebaudo)

*****

OPENING SNAPSHOT: EUROPE WAVERS BEFORE THE ECB (0725 GMT)

We're off to an uncertain start in Europe this morning with investors awaiting for the ECB
to provide fresh direction with hints of more stimulus to soften the strength of the euro
against the dollar.

Major regional benchmarks were down slightly, following mild initial gains. The STOXX 600 is
last down 0.15%.

Pandemic-hit travel and leisure stocks are up 0.7% with British Airways owner IAG
up over 2% after launching a fully underwritten 2.7 billion euros capital increase to beef up
its balance sheet.

Games Workshop is up an outstanding 18% after saying trading in the three months to
end August topped its expectations.

UK listed housebuilders are doing well after an upbeat RICS survey showed that the
post-lockdown surge in the housing market intensified in August with prices hitting a 4-year
high. Taylor Wimpey and Barratt are both up more than 2%.

Italy's Nexi is up 5% after a report said the payment firms and SIA are close to
clearing a major hurdle to a potential merger.

Weaker oil and basic material stocks weighed. Tech was lower too.

(Danilo Masoni)

*****

ON OUR RADAR: EURO, IAG CAP RISE AND DEALMAKING (0644 GMT)

As we said the European Central Bank's policy meeting and any signals from the central bank
about future easing measures will be the key highlight for investors today.

The euro and bond markets are likely to be most sensitive to ECB news, but we'll be
keeping an eye on stocks too, especially on rate-sensitive sectors like banks.

Besides that, on the corporate front, it doesn't look there is any earth shattering news out
there so far.

This will be the first full session for investors to digest LVMH's decision to
walk away from its planned $16 billion takeover of Tiffany. LVMH was little changed on
the news yesterday.

Airlines, which have been heavily hit by travel restrictions adopted to fight the COVID
pandemic, continue to be under pressure. British Airways owner IAG launched a heavily
discounted 2.7 billion euros capital increase to beef up its finances. The good news here is
that it's fully underwritten.

GlaxoSmithKline said the U.S health regulator approved its lung disease drug Trelegy
Ellipta for expanded use, making it the first inhaler delivering three drugs at once to be
prescribed for uncontrolled asthma in the country.

In M&A, Equinor raised $1.1 billion by selling stakes in offshore wind power
development projects to BP, while in Italy, the government said it's ready to use its
vetting "golden" powers to ensure the Milan exchange is not sold to an unacceptable bidder.

Meanwhile in France, utility Suez reiterated its opposition to Veolia’s
offer for Engie's stake in Suez, saying it undervalued Suez.

Among smaller companies, share placement are expected to put under pressure Ferroamp
, Carasent, and Kojamo.

In earnings news, an upbeat outlook from Akzo Nobel could lift its shares, while Dixons
reported a 56% drop mobile phone in the 17 weeks to end-August.

(Danilo Masoni)

*****

MORNING CALL: IT'S ECB DAY (0530 GMT)

Regardless of whether it's going to have any big impact on markets today the focus is
squarely on the European Central Bank's policy meeting.

The consensus is that rates will remain unchanged although investors expect signals from the
central bank which could possibly weaken the euro.

On the background are still worries over rising Brexit risks and possible further turbulence
in tech stocks, and it may be little surprise that following yesterday's rebound in Europe and
the U.S., futures are giving mixed signals at the moment.

The Euro STOXX 500 futures are up 0.3%, FTSE 100 futures are down 0.3% and Wall Street
futures are moving flat to slightly higher.

(Danilo Masoni)

*****

More News
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more
22 Nov 2023 09:48

LONDON BROKER RATINGS: RBC cuts HSBC; Liberum cuts Glencore

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.